High-risk localised prostate cancer: Multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy Journal Article
| Author: | Eastham, J. A. |
| Article Title: | High-risk localised prostate cancer: Multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy |
| Abstract: | For patients with newly diagnosed prostate cancer, clinical tumour stage, Gleason score of the diagnostic biopsy specimen and serum prostate-specific antigen (PSA) level can be combined to identify a group of men at increased risk of treatment failure after radiotherapy or radical prostatectomy. For these high-risk, but still clinically localised prostate cancers, multimodal treatment strategies may result in improved cancer control outcomes. Indeed, in the setting of clinical stage T3-T4 tumours, the combination of radiotherapy followed by hormonal therapy has improved patient survival. The benefits of adjuvant or neoadjuvant hormonal and/or chemotherapy followed by radical prostatectomy in this setting are unclear, but are the subject of ongoing or planned Phase III clinical trials. These studies will help define the role of multimodal treatment strategies in this high-risk patient population. |
| Keywords: | cancer survival; treatment outcome; treatment failure; clinical trial; drug tolerability; histopathology; neutropenia; review; cancer localization; cancer combination chemotherapy; drug efficacy; paclitaxel; combined modality therapy; neoadjuvant therapy; chemotherapy; cancer staging; antineoplastic agent; prostate specific antigen; quality of life; erythropoietin; etoposide; blood toxicity; antineoplastic combined chemotherapy protocols; deep vein thrombosis; vinblastine; risk assessment; docetaxel; cancer hormone therapy; febrile neutropenia; prostate cancer; prostatic neoplasms; prostatectomy; thromboembolism; prostate biopsy; mitoxantrone; warfarin; radical prostatectomy; high risk population; antiandrogen; hydrocortisone; antineoplastic agents, hormonal; corticosteroid; clinical trials; granulocytopenia; anticoagulant agent; estramustine; humans; human; male |
| Journal Title: | Expert Opinion on Emerging Drugs |
| Volume: | 8 |
| Issue: | 2 |
| ISSN: | 1472-8214 |
| Publisher: | Informa Healthcare |
| Date Published: | 2003-11-01 |
| Start Page: | 291 |
| End Page: | 295 |
| Language: | English |
| DOI: | 10.1517/14728214.8.2.291 |
| PUBMED: | 14661990 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 25 September 2014 -- Source: Scopus |
